secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0001724521-24-000099
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus reports Phase 2 EDGE-Gastric interim data: median PFS 12.9 months, ORR 58.5% in upper GI cancers
--------------------------------------------------------------------------------

- Median PFS of 12.9 months (95% CI 9.8–13.8) across 41 patients in the domvanalimab+zimberelimab+chemo arm.
- Confirmed ORR 58.5%, with 3 complete responses and median DOR of 12.4 months (95% CI 9.9–NE).
- PD-L1-high subgroup (TAP ≥5%) showed median PFS 13.8 months and ORR 68.8% (n=16).
- No unexpected safety signals; infusion-related reactions in 19.5% of subjects, mostly chemotherapy-related.
- Data cutoff March 12, 2024; results posted to company website on June 2, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000172452124000099/0001724521-24-000099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000172452124000099/rcus-20240602.htm
  HTML page:      https://secwatch.observer/filing/0001724521-24-000099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer